This case highlights the potential of immunotherapy and anti-angiogenic drugs as a viable treatment option for thoracic SMARCA4-deficient undifferentiated tumors, particularly in patients with comorbid conditions such as AIDS. Here, SMARCA4 is linked to AIDS.